Preprocedural statin medication reduces the extent of periprocedural non-Q-wave XXXX .

@entity1 @entity32 @entity296 @entity1423 @entity908 @entity1780 @entity10020 @entity2453 @entity583 @entity850
BACKGROUND: Stenting-related @entity296 has been recognized as a frequent and prognostically important event, the extent of which depends on microcirculatory impairment in association with @entity1423 , @entity32 , and increased oxidative stress. Recent studies underscored the non-lipid-lowering effects of @entity2453 ( @entity2453 ) reductase inhibitors (statins) with antithrombotic, antiinflammatory, and antioxidative aspects. Thus, we tested the hypothesis that preprocedural statin therapy is associated with a reduction in the extent of stenting-related @entity296 . METHODS AND RESULTS: We stratified 296 consecutive @entity1 who were undergoing stenting of a de novo @entity850 according to the preprocedural status of statin therapy (229 statin-treated and 67 control @entity1 ). Incidence of periprocedural @entity296 was assessed by analysis of @entity908 kinase (CK; upper limit of normal [ULN] 70 IU/L for @entity1 , 80 IU/L for @entity1 ) and @entity10020 ( @entity10020 ; bedside test; threshold 0.1 ng/mL) before and 6, 12, and 24 hours after the intervention. Relative to control @entity1 , the incidence of CK elevation >3x ULN was more than 90% lower in statin-treated @entity1 (0.4% versus 6.0%, P=0.01). @entity1780 therapy was the only factor independently associated with a lower risk of CK elevation >3x ULN (OR: 0.08, 95% CI: 0.01 to 0.75; P=0.03). The overall incidences of CK and @entity10020 elevation were slightly lower in statin-treated than in control @entity1 (14.4% versus 20.9%, P=0.3, and 17.9% versus 22.4%, P=0.5, respectively). CONCLUSIONS: Preprocedural statin therapy is associated with a reduction in the incidence of larger-sized, stenting-related @entity583 . Prospective, randomized trials are warranted to further assess this cardioprotective effect of statins in coronary intervention.
